Oktober 22. 2024

4th Annual Passport to Proficiency on the Essentials of Hatch-Waxman and BPCIA

Share

FDA Regulatory partner, George O’Brien will discuss “Comprehending the Intricacies of Non-Patent/ Regulatory Exclusivity” during ACI’s Hatch-Waxman and BPCIA Proficiency Series, a virtual three-week program designed to provide new lawyers and executives for the life sciences industry with a solid foundation for understanding the essentials as well as the intricacies of Hatch-Waxman and BPCIA litigation and regulation.

The panel will discuss:

  • Understanding which drug products are eligible for regulatory exclusivity
    • small biologics v. biologics
  • The different modes and methods of regulatory exclusivity (non-patent)
    • NCE (new chemical entity): 5 years marketing exclusivity/5 years data exclusivity
    • indication (new indication or use): 3 years marketing exclusivity
    • NDF (new dosage formulation)
    • ODE (orphan drug exclusivity)
    • PED (pediatric exclusivity)
  • FD&C 505b2 (alternate pathway to ANDA) a/k/a paper NDA
  • What role does the FDA play in regulating these modes of exclusivity?
  • When are each of these methods sought?
  • Using trade dress as means of exclusivity

For more information and to register, please visit the event webpage.

verwandte Beratungsfelder und Industrien

Beratungsfelder

Industrien

Stay Up To Date With Our Insights

See how we use a multidisciplinary, integrated approach to meet our clients' needs.
Subscribe